Aug 14, 2026 · 11 min · 9 segments
Send us Fan Mail Everyone points at Big Pharma—but the real bottleneck is hidden in plain sight. 👉 Get your free guide…
Jay ChaplinHost
The second most common comment I see online is, "Pharma companies are greedy, and they won't allow a cure for cancer because it doesn't make them money." Now, I've spoken about that because I think it, it puts the emphasis in the wrong place.

That's not actually the way pharma companies operate, and it takes away your leverage and your ability to understand the way things work.

Now, this is an important discussion because just like with the Antiva episode, understanding what the real causes of these things are gives us more leverage and more ability to actually have impact.

So today, a lovely piece came out, and it is really hammering home something that I have talked about before.

And what's the evidence around that? Actually, there's fantastic evidence around that.

They work perfectly well, and the cost for maintaining somebody with hemophilia on standard treatment today is three hundred thousand dollars per year every year for the rest of their life, okay? So you say 40 years of treatment, and that's 12 million dollars.

So a pharma company can expect to make 12 million dollars off of one hemophilia patient.

Why would they do anything else? And yet, we have pharma company-developed, licensed, fully available gene therapies for hemophilia, which cure it with one treatment.

It's one treatment instead of getting infusions every month for the rest of their life.

The second most common comment I see online is, "Pharma companies are greedy, and they won't allow a cure for cancer because it doesn't make them money." Now, I've spoken about that because I think it, it puts the emphasis in the wrong place.

That's not actually the way pharma companies operate, and it takes away your leverage and your ability to understand the way things work.

Now, this is an important discussion because just like with the Antiva episode, understanding what the real causes of these things are gives us more leverage and more ability to actually have impact.

So today, a lovely piece came out, and it is really hammering home something that I have talked about before.

And what's the evidence around that? Actually, there's fantastic evidence around that.

They work perfectly well, and the cost for maintaining somebody with hemophilia on standard treatment today is three hundred thousand dollars per year every year for the rest of their life, okay? So you say 40 years of treatment, and that's 12 million dollars.

So a pharma company can expect to make 12 million dollars off of one hemophilia patient.

Why would they do anything else? And yet, we have pharma company-developed, licensed, fully available gene therapies for hemophilia, which cure it with one treatment.

It's one treatment instead of getting infusions every month for the rest of their life.
The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode
No account is needed to search Radar.